Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2016 07:00 ET | Source: Immunomedics, Inc.

Immunomedics to Present Updated Clinical Trial Results for Antibody-Drug Conjugates at Cancer Conference

MORRIS PLAINS, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that two abstracts have been accepted for oral presentation in a Clinical Trials...
March 14, 2016 16:30 ET | Source: Immunomedics, Inc.

Immunomedics Provides Update on Phase 3 PANCRIT-1 Trial of Clivatuzumab Tetraxetan in Patients With Advanced Pancreatic Cancer

MORRIS PLAINS, N.J., March 14, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company is terminating the Phase 3 PANCRIT-1 trial with yttrium-90-labeled (90Y)...
March 08, 2016 07:00 ET | Source: Immunomedics, Inc.

Immunomedics Develops Novel Antibody-Based Products for Autoimmune Disease and Cancer Therapy

MORRIS PLAINS, N.J., March 08, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that the issuance of U.S. patent no. 9,278,129 for the Company’s new patent family...
March 02, 2016 07:00 ET | Source: Immunomedics, Inc.

Immunomedics to Present at Cowen and Company 36th Annual Health Care Conference

MORRIS PLAINS, N.J., March 02, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company will present at the Cowen and Company 36th Annual Health Care...
February 26, 2016 01:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Termination of Epratuzumab Licensing Agreement With UCB

MORRIS PLAINS, N.J., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced receipt of a notice from UCB terminating the May 2006 Development, Collaboration and...
February 05, 2016 09:28 ET | Source: Immunomedics, Inc.

U.S. Food and Drug Administration (FDA) Grants Breakthrough Therapy Designation to Immunomedics for Sacituzumab Govitecan for the Treatment of Patients With Triple-Negative Breast Cancer

MORRIS PLAINS, N.J., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132,...
February 03, 2016 16:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Second Quarter Fiscal 2016 Results and Clinical Program Developments

MORRIS PLAINS, N.J., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today reported financial results for the second quarter ended December 31, 2015. The Company also...
January 28, 2016 07:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Conference Call and Webcast for Second Quarter Fiscal 2016 Financial Results

MORRIS PLAINS, N.J., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that it will host a conference call and live audio webcast on Thursday, February 4, 2016 at...
January 05, 2016 07:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces New Patent Covering the Use of Antibody-SN-38 Conjugates Combination

MORRIS PLAINS, N.J., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced the issuance of U.S. patent no. 9,226,973 for additional claims under the patent family...
December 10, 2015 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Reports Continuing Positive Results With Sacituzumab Govitecan in Heavily Pre-Treated Metastatic Triple-Negative Breast Cancer Patients

– Objective Response Rate (ORR) of 31%, 78% Confirmed – – Median Progression-Free Survival (PFS) was 6.0 Months, 58% Maturity – – Interim Results...